Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $6 | $4 | $4 | $4 |
| % Growth | 39.6% | 7% | 5.3% | – |
| Cost of Goods Sold | $3 | $3 | $2 | $2 |
| Gross Profit | $2 | $1 | $2 | $1 |
| % Margin | 37.8% | 36.5% | 40.7% | 35.6% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $2 | $2 |
| Operating Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -6% | -27.3% | -17.5% | -28.9% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -9.5% | -30.9% | -20.7% | -26% |
| EPS | -0.32 | -0.76 | -0.63 | -0.63 |
| % Growth | 57.9% | -20.6% | 0% | – |
| EPS Diluted | -0.32 | -0.76 | -0.63 | -0.63 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -12.4% | -26.4% | -16.6% | -28% |